semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, double‐blind,
Description
GLP-1 as a target for therapeutic intervention
![semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, doubleblind,](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/d856dae6-4870-4b06-8710-830fb603f2cb/dom15624-fig-0002-m.png)
J., Sud, V., Zhang, H., Tsung, A
![semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, doubleblind,](https://www.researchgate.net/publication/360151402/figure/fig1/AS:1148215906844674@1650767413956/Pharmacokinetic-behavior-of-ALT-801-and-semaglutide-in-C57Bl-6J-mice-following.png)
Lysine at position 34 of GLP-1 is replaced by arginine
![semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, doubleblind,](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-021-01025-x/MediaObjects/40262_2021_1025_Fig6_HTML.png)
Your bodys response to the current dose matters just as much as how long you have been on it
Originally developed to treat Type 2 diabetes , this injectable medication has now emerged as a powerful tool for safe, sustained weight loss under the guidance of a healthcare professional
![semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, doubleblind,](https://ars.els-cdn.com/content/image/1-s2.0-S1570023223000983-gr3.jpg)
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy [10]
![semaglutide hepatic impairment pharmacokinetics Human of [ 3 H]-semaglutide and metabolites detected A phase 1, randomized, doubleblind,](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb7/4418331/1809c5c2c13e/jcph0055-0497-f2.jpg)